Sorry, you need to enable JavaScript to visit this website.

A Study Of PF-05212384 In Combination with Other Anti-Tumor Agents and in Combination with Cisplatin in Patients with Triple Negative Breast Cancer (TNBC) in an Expansion Arm

A Phase 1b Open-Label Three-Arm Multi-Center Study to Assess the Safety and Tolerability of PF-05212384 (PI3K/mTOR Inhibitor) in Combination with Other Anti-Tumor Agents

Category & Conditions: Cancer
Medicine: Gedatolisib (PF-05212384) VIZIMPRO® TABLETS(DACOMITINIB)
ClinicalTrials.gov Identifier (NCT): NCT01920061
Protocol ID: B2151002
    Share
PrintDownload
Open Plain Language Summary Result: Click here